Antithrombotic effects of magnesium sulfate in in vivo experiments.
In this study, magnesium sulfate was effective in reducing the mortality of adenosine diphosphate-induced acute pulmonary thromboembolism in mice, when it was administered intravenously at doses of 100 and 200 microg/g body weight. In addition, intravenous injections of magnesium sulfate (100 and 200 microg/g) significantly prolonged bleeding time in the severed mesenteric arteries of rats by approximately 1.7- and 1.9-fold, respectively, compared with normal saline. Continuous infusion of magnesium sulfate (20 microg/g per minute) for 10 minutes also significantly increased the bleeding time by approximately 1.7-fold, and the bleeding time returned to baseline within 60 minutes of cessation of magnesium sulfate infusion. On the other hand, platelet thrombi formation was induced by irradiating mesenteric venules with filtered light in mice pretreated with intravenous fluorescein sodium. When magnesium sulfate was administered at 300 microg/g during induction of platelet plug formation with 10 microg/kg fluorescein sodium, occlusion time was not significantly prolonged, but a dose of 600 microg/g did significantly prolong the occlusion time. Furthermore, aspirin (250 microg/g) also showed a similar activity in this experiment in prolonging the occlusion time. In conclusion, these results suggest that magnesium sulfate has an effective antithrombotic activity in vivo, and treatment with magnesium sulfate may lower the risk of thromboembolic-related disorders.
Sheu
Joen R
JR
Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan. sheujr@tmu.edu.tw
Hsiao
George
G
Shen
Ming Y
MY
Lee
Yen M
YM
Yen
Mao H
MH
D000244:Adenosine Diphosphate; D000818:Animals; D001760:Bleeding Time; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D019793:Fluorescein; D007275:Injections, Intravenous; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000494:pharmacology*; D008638:Mesenteric Arteries; D051381:Rats; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
D005343:Fibrinolytic Agents; D000244:Adenosine Diphosphate; D008278:Magnesium Sulfate; D019793:Fluorescein